STLN Stock Analysis: The Oncology Institute | NASDAQ

NASDAQ, USA | Market Cap: 499m USD | 12M Return: 51.2% | Charts, Fundamentals & Technical Analysis

Total Rating 21
Safety 28
Buy Signal 1.28
Market Cap: 499M
Avg Turnover: 8.67M
Risk 3d forecast
Volatility148%
VaR 5th Pctl23.5%
VaR vs Median-3.52%
Reward TTM
Sharpe Ratio0.87
Rel. Str. IBD96.7
Rel. Str. Peer Group-
Character TTM
Beta0.808
Beta Downside-0.516
Hurst Exponent0.402
Drawdowns 3y
Max DD94.82%
CAGR/Max DD0.94
CAGR/Mean DD2.27
EPS (Earnings per Share) EPS (Earnings per Share) of STLN over the last years for every Quarter: "2022-12": null, "2023-12": null, "2024-12": null, "2025-03": null, "2025-06": -0.15, "2025-09": -0.14, "2025-12": -0.06, "2026-03": -0.02, "2026-06": -0.08,
Last SUE: -0.21
Qual. Beats: 0
Revenue Revenue of STLN over the last years for every Quarter: 2022-12: 252.483, 2023-12: 324.239, 2024-12: 393.412, 2025-03: 104.406, 2025-06: 119.802, 2025-09: 136.564, 2025-12: 141.957, 2026-03: 147.441, 2026-06: null,
Rev. CAGR: 24.52%
Rev. Trend: 99.8%
Qual. Beats: 0

Warnings

Negative Equity With Losses
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Extended 3d

Tailwinds

Squeeze
Rs Leader
Confidence
Ep Pivot

Seasonality

Not enough history
Description: STLN The Oncology Institute
Headlines to Watch Out For
Piotroski VR-10 (Strict) 3.0
Net Income: -43.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.15 > 0.02 and ΔFCF/TA 3.20 > 1.0
NWC/Revenue: 6.87% < 20% (prev 12.02%; Δ -5.14% < -1%)
CFO/TA -0.13 > 3% & CFO -21.8m > Net Income -43.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.47 > 1.5 & < 3
Outstanding Shares: last quarter (100.0m) vs 12m ago 12.42% < -2%
Gross Margin: 15.12% > 18% (prev 13.73%; Δ 1.39% > 0.5%)
Asset Turnover: 328.5% > 50% (prev 239.9%; Δ 88.66% > 0%)
Interest Coverage Ratio: -4.28 > 6 (EBIT TTM -32.7m / Interest Expense TTM 7.64m)
Altman Z'' -5.26
A: 0.22 (Total Current Assets 116.9m - Total Current Liabilities 79.4m) / Total Assets 168.2m
B: -1.63 (Retained Earnings -273.9m / Total Assets 168.2m)
C: -0.20 (EBIT TTM -32.7m / Avg Total Assets 166.1m)
D: -0.09 (Book Value of Equity -16.3m / Total Liabilities 184.5m)
Altman-Z'' = -5.26 = D
Beneish M -3.08
DSRI: 0.85 (Receivables 58.1m/49.3m, Revenue 545.8m/393.4m)
GMI: 0.91 (GM 13.73% / 15.12%)
AQI: 0.81 (AQ_t 0.11 / AQ_t-1 0.13)
SGI: 1.39 (Revenue 545.8m / 393.4m)
TATA: -0.13 (NI -43.5m - CFO -21.8m) / TA 168.2m)
Beneish M = -3.08 (Cap -4..+1) = AA
What is the price of STLN shares?

As of August 10, 2026, the stock is trading at USD 6.41 with a total of 6,611,234 shares traded. Over the past week, the price has changed by +31.89%, over one month by +9.57%, over three months by +59.85% and over the past year by +51.18%.

Current recommended Stop Loss: 5.90 (which is 8% or 1.5 ATR below the current price).

Is STLN a buy, sell or hold?

The Oncology Institute has no consensus analysts rating.

The Oncology Institute (STLN) - Fundamental Data Overview as of 08 August 2026
Market Cap USD = 498.9m (498.9m USD * 1.0 USD.USD)
P/S = 0.9142
P/B = 0.7617
Revenue TTM = 545.8m USD
EBIT TTM = -32.7m USD
EBITDA TTM = -25.9m USD
Long Term Debt = 78.6m USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 26.2m USD (Leases only: 26.2m)
Net Debt = -4.03m USD (calculated: Debt 26.2m - CCE 30.3m)
Enterprise Value = 494.9m USD (498.9m + Debt 26.2m - CCE 30.3m)
Interest Coverage Ratio = -4.28 (Ebit TTM -32.7m / Interest Expense TTM 7.64m)
EV/FCF = -19.24x (Enterprise Value 494.9m / FCF TTM -25.7m)
FCF Yield = -5.20% (FCF TTM -25.7m / Enterprise Value 494.9m)
FCF Margin = -4.71% (FCF TTM -25.7m / Revenue TTM 545.8m)
Net Margin = -7.97% (Net Income TTM -43.5m / Revenue TTM 545.8m)
Gross Margin = 15.12% ((Revenue TTM 545.8m - Cost of Revenue TTM 463.3m) / Revenue TTM)
Gross Margin QoQ = 15.81% (prev 16.04%)
Tobins Q-Ratio = 2.94 (Enterprise Value 494.9m / Total Assets 168.2m)
Interest Expense / Debt = 29.11% (Interest Expense 7.64m / Debt 26.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -25.8m (EBIT -32.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.47 (Total Current Assets 116.9m / Total Current Liabilities 79.4m)
 Debt / Equity = -1.61 (negative equity) (Debt 26.2m / totalStockholderEquity, last quarter -16.3m)
 Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -4.03m / EBITDA -25.9m)
 Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -4.03m / FCF TTM -25.7m)
 Total Stockholder Equity = -13.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.19% (Net Income -43.5m / Total Assets 168.2m)
 RoE = 326.8% (negative equity) (Net Income TTM -43.5m / Total Stockholder Equity -13.3m)
 RoCE = -50.06% (EBIT -32.7m / Capital Employed (Equity -13.3m + L.T.Debt 78.6m))
 RoIC = -41.92% (negative operating profit) (NOPAT -25.8m / Invested Capital 61.6m)
 WACC = 9.53% (E(498.9m)/V(525.2m) * Re(8.82%) + D(26.2m)/V(525.2m) * Rd(29.11%) * (1-Tc(0.21)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
 [DCF] Fair Price = unknown (Cash Flow -25.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 99.77 | Revenue CAGR: 24.52% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.04 | Chg30d=+20.00% | Revisions=+17% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.14 | Chg30d=+8.00% | Revisions=+57% | GrowthEPS=+74.4% | GrowthRev=+30.4%
EPS next Year (2027-12-31): EPS=-0.03 | Chg30d=+68.75% | Revisions=+25% | GrowthEPS=+81.9% | GrowthRev=+25.9%
[Analyst] Revisions Ratio: +55% (up=7, down=1)